Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 3/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | ECE2 | P0DPD6 | 2/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956188 | 1.00 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDGAASTAT3 | |
| Formamide SCHEMBL9731457 | 0.81 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDGAASTAT3 | |
| SCHEMBL2894808 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EHPGDGAASTAT3 | |
| SCHEMBL9731454 | 0.79 | EGFR (0.45) | ALDH1A1KDM4EHPGDGAASTAT3 | |
| SCHEMBL7891555 | 0.78 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDGAASTAT3 | |
| SCHEMBL2015910 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDGAASTAT3 | |
| SCHEMBL29956438 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL14911960 | 0.77 | TDP1 (0.53) | ALDH1A1KDM4EHPGDGAASTAT3 | |
| SCHEMBL6965074 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDGAAGLA | |
| SCHEMBL28289877 | 0.77 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDGAASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106163509-A | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2016-11-23 | — | — | CN | claimed |
| CN-106132406-A | β substituted γ aminoacid and analog as chemotherapeutics | 夸德里加生物科学公司 | 2016-11-16 | — | — | CN | claimed |
| CN-117964645-A | Synthesis method and application of 8-hydroxyquinoline aldehyde N-O pyridine bisacylhydrazone tetranuclear dysprosium cluster compound | 广西医科大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-116589403-A | 3-hydroxyquinoline-2-ketone compound and synthetic method and application thereof | 浙江工业大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-116589403-A | 3-hydroxyquinoline-2-ketone compound and synthetic method and application thereof | 浙江工业大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-116589403-A | 3-hydroxyquinoline-2-ketone compound and synthetic method and application thereof | 浙江工业大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-111689944-B | Quinoline tryptamine heterozygote and application thereof in preparation of medicine for treating Alzheimer disease | 中山大学 | 2021-11-16 | — | — | CN | disclosed |
| CN-111689944-A | Quinoline tryptamine heterozygote and application thereof in preparation of medicine for treating Alzheimer disease | 中山大学 | 2020-09-22 | — | — | CN | disclosed |
| EP-3044284-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-11-13 | — | — | EP | disclosed |
| CN-106163509-B | β -substituted β -amino acids and analogs as chemotherapeutic agents | 夸德里加生物科学公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-108026026-A | Beta-amino acids and analog and its application as the β-substituted of chemotherapeutics | 夸德里加生物科学公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008124323-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| CN-1688549-A | Compound having TGF-beta inhibitory activity and medicinal composition containing the same | KIRIN BREWERY (JP) | 2005-10-26 | — | — | CN | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
| US-5421897-A | Applying liquid composition to surface contaminated with lead, solidifying into matrix which sequesters lead, removing matrix | GRAWE JOHN (US) | 1995-06-06 | — | — | US | disclosed |
| US-4002564-A | Cation-exchange resins having cross-linked vinyl aromatic polymer matrix with attached amino alkylene phosphonic acid groups, their use, and preparation | DIAMOND SHAMROCK CORPORATION (US) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | ALDH1A1 1257/4885KDM4E 1176/4885HPGD 1553/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | ALDH1A1 1845/4885KDM4E 1066/4885HPGD 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.